Bio-Techne Corporation (TECH)

Market Cap	8.54B
Revenue (ttm)	1.22B
Net Income (ttm)	73.40M
Shares Out	156.77M
EPS (ttm)	0.46
PE Ratio	118.89
Forward PE	27.23
Dividend	$0.32 (0.59%)
Ex-Dividend Date	Aug 18, 2025

Volume	398,321
Open	53.18
Previous Close	52.83
Day's Range	52.92 - 54.80
52-Week Range	46.01 - 80.95
Beta	1.39
Analysts	Buy
Price Target	69.82 (+28.2%)
Earnings Date	Aug 6, 2025

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 9, 1989
• Employees: 3,050
• Stock Exchange: NASDAQ
• Ticker Symbol: TECH
• Website: https://www.bio-techne.com

Financial Performance

In 2025, Bio-Techne's revenue was $1.22 billion, an increase of 5.23% compared to the previous year's $1.16 billion. Earnings were $73.40 million, a decrease of -56.33%.

Analyst Forecast

According to 12 analysts, the average rating for TECH stock is "Buy." The 12-month stock price target is $69.82, which is an increase of 28.20% from the latest price.

Price Target

$69.82

(28.20% upside)

Analyst Consensus: Buy